Advertisement

Prevention of post-operative recurrence of Crohn's disease among patients with prior anti-TNFα failure: A retrospective multicenter study

Published:September 30, 2022DOI:https://doi.org/10.1016/j.dld.2022.09.004

      Abstract

      Background

      Anti-TNFα are recommended for preventing Crohn's disease (CD) postoperative recurrence (POR) in patients with risk factors. However, few data exploring anti-TNFα efficacy in patients with preoperative anti-TNFα failure are available so far.

      Aims

      The aim of the present study was to compare the efficacy of anti-TNFα with other biologics and immunosuppressants to prevent POR in this setting.

      Methods

      Consecutive CD patients who underwent bowel resection between January 2010 and December 2019 after failure of at least one anti-TNFα were retrospectively included among three tertiary centers if they started a postoperative medical prophylaxis within the three months after index surgery. The main outcome was to compare rates of objective recurrence (endoscopic or radiological recurrence in absence of colonoscopy) between patients treated with an anti-TNFα agent or another treatment as prevention of POR.

      Results

      Among the 119 patients included, 71 patients received an anti-TNFα (26 infliximab, 45 adalimumab) and 48 another treatment (18 ustekinumab, 7 vedolizumab, 20 azathioprine and 3 methotrexate) to prevent POR. Rates of objective recurrence at two years were 23.9% in patients treated with anti-TNFα and 44.9% in the others (p = 0.011).

      Conclusion

      Anti-TNFα remained an effective option to prevent POR for patients operated upon with previous anti-TNFα failure.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Annese V.
        • Duricova D.
        • Gower-Rousseau C.
        • et al.
        Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the epidemiology committee of ECCO.
        J Crohns Colitis. 2016; 10: 216-225
        • Schnitzler F.
        • Fidder H.
        • Ferrante M.
        • et al.
        Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
        Gut. 2009; 58: 492-500
        • Danese S.
        • Fiorino G.
        • Reinisch W.
        Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy.
        Aliment Pharmacol Ther. 2011; 34: 1-10
        • Sandborn W.J.
        • Feagan B.G.
        • Rutgeerts P.
        • et al.
        Vedolizumab as induction and maintenance therapy for Crohn's disease.
        N Engl J Med. 2013; 369: 711-721
        • Sandborn W.J.
        • Gasink C.
        • Gao L.-.L.
        • et al.
        Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
        N Engl J Med. 2012; 367: 1519-1528
        • Khoudari G.
        • Mansoor E.
        • Click B.
        • et al.
        Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study.
        Clinical Gastroenterol Hepatol. 2020; S1542356520313975
        • Feagan B.G.
        • Panaccione R.
        • Sandborn W.J.
        • et al.
        Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
        Gastroenterology. 2008; 135: 1493-1499
        • Frolkis A.D.
        • Dykeman J.
        • Negrón M.E.
        • et al.
        Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies.
        Gastroenterology. 2013; 145: 996-1006
        • Kalman T.D.
        • Everhov Å.H.
        • Nordenvall C.
        • et al.
        Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990-2014.
        Br J Surg. 2020; 107: 1529-1538
        • Rutgeerts P.
        • Geboes K.
        • Vantrappen G.
        • et al.
        Predictability of the postoperative course of Crohn's disease.
        Gastroenterology. 1990; 99: 956-963
        • Buisson A.
        • Chevaux J.-.B.
        • Allen P.B.
        • et al.
        Review article: the natural history of postoperative Crohn's disease recurrence.
        Aliment Pharmacol Ther. 2012; 35: 625-633
        • Gionchetti P.
        • Dignass A.
        • Danese S.
        • et al.
        3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations.
        J Crohns Colitis. 2017; 11: 135-149
        • Erős A.
        • Farkas N.
        • Hegyi P.
        • et al.
        Anti-TNFα agents are the best choice in preventing postoperative Crohn's disease: a meta-analysis.
        Digestive and Liver Disease. 2019; 51: 1086-1095
        • Regueiro M.
        • Feagan B.G.
        • Zou B.
        • et al.
        Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection.
        Gastroenterology. 2016; 150: 1568-1578
        • Collins M.
        • Sarter H.
        • Gower-Rousseau C.
        • et al.
        Previous exposure to multiple anti-TNF is associated with decreased efficiency in preventing postoperative Crohn's disease recurrence.
        J Crohns Colitis. 2017; 11: 281-288
        • Gomollón F.
        • Dignass A.
        • Annese V.
        • et al.
        3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management.
        ECCOJC. 2017; 11: 3-25
        • Satsangi J.
        • Silverberg M.S.
        • Vermeire S.
        • et al.
        The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.
        Gut. 2006; 55: 749-753
        • Papamichael K.
        • Cheifetz A.S.
        • Melmed G.Y.
        • et al.
        Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases.
        Clin Gastroenterol Hepatol. 2019; 17 (e3): 1655-1668
        • Sailer J.
        • Peloschek P.
        • Reinisch W.
        • et al.
        Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy.
        Eur Radiol. 2008; 18: 2512-2521
        • Baillet P.
        • Cadiot G.
        • Goutte M.
        • et al.
        Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.
        World J Gastroenterol. 2018; 24: 641-650
        • De Cruz P.
        • Kamm M.A.
        • Hamilton A.L.
        • et al.
        Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis.
        Aliment Pharmacol Ther. 2015; 42: 867-879
        • De Cruz P.
        • Kamm M.A.
        • Hamilton A.L.
        • et al.
        Crohn's disease management after intestinal resection: a randomised trial.
        Lancet. 2015; 385: 1406-1417
        • Rivière P.
        • Vermeire S.
        • Irles-Depe M.
        • et al.
        Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies.
        Clin Gastroenterol Hepatol. 2021; 19 (e1): 713-720
        • Hammoudi N.
        • Auzolle C.
        • Tran Minh M.-.L.
        • et al.
        Postoperative endoscopic recurrence on the neoterminal ileum but not on the anastomosis is mainly driving long-term outcomes in Crohn's disease.
        Am J Gastroenterol. 2020; 115: 1084-1093
        • Savarino E.
        • Bodini G.
        • Dulbecco P.
        • et al.
        Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
        Am J Gastroenterol. 2013; 108: 1731-1742
        • Assa A.
        • Bronsky J.
        • Kolho K.-.L.
        • et al.
        Anti-TNFα treatment after surgical resection for Crohnʼs disease is effective despite previous pharmacodynamic failure.
        Inflamm. Bowel Dis. 2017; 23: 791-797
        • Auzolle C.
        • Nancey S.
        • Tran-Minh M.-.L.
        • et al.
        Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study.
        Aliment Pharmacol Ther. 2018; 48: 924-932
        • Buisson A.
        • Chevaux J.-.B.
        • Bommelaer G.
        • et al.
        Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence.
        Digestive and Liver Disease. 2012; 44: 453-460
        • Cottone M.
        • Rosselli M.
        • Orlando A.
        • et al.
        Smoking habits and recurrence in Crohn's disease.
        Gastroenterology. 1994; 106: 643-648
        • Bernell O.
        • Lapidus A.
        • Hellers G.
        Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease.
        Br J Surg. 2000; 87: 1697-1701
        • Wasmann K.A.T.G.M.
        • van Amesfoort J.
        • van Montfoort M.L.
        • et al.
        The predictive value of inflammation at ileocecal resection margins for postoperative Crohn's recurrence: a cohort study.
        Inflamm. Bowel Dis. 2020; 26: 1691-1699
        • Singh S.
        • George J.
        • Boland B.S.
        • et al.
        Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis.
        J Crohns Colitis. 2018; 12: 635-643
        • Schaefer M.
        • Laurent V.
        • Grandmougin A.
        • et al.
        A magnetic resonance imaging index to predict Crohn's disease postoperative recurrence: the MONITOR index.
        Clin Gastroenterol Hepatol. 2021; (S1542-3565(21)00699-6)
        • Mesonero F.
        • Castro-Poceiro J.
        • Benítez J.M.
        • et al.
        Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registry.
        Aliment Pharmacol Ther. 2021; 53: 1021-1029
        • Yamada A.
        • Komaki Y.
        • Patel N.
        • et al.
        The use of vedolizumab in preventing postoperative recurrence of Crohn's disease.
        Inflamm Bowel Dis. 2018; 24: 502-509
        • Mañosa Ciria M.
        • Fernandez-Clotet A.
        • Hernández-Camba A.
        • et al.
        P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in Crohn's disease. Data from clinical practice from the eneida registry.
        J Crohn's Colitis. 2020; 14 (S410–S410)
        • Buisson A.
        • Nancey S.
        • Manlay L.
        • et al.
        Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United.
        European Gastroenterol J. 2021; 9: 552-560
      1. Mañosa M., Fernández-Clotet A., Nos P., et al. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: results from the ENEIDA registry. Digestive and Liver Disease [Internet]. 2022 [cited 2022 Aug 24];0. Available from: https://www.dldjournalonline.com/article/S1590-8658(22)00618-1/fulltext.

        • Mowat C.
        • Arnott I.
        • Cahill A.
        • et al.
        Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.
        Lancet Gastroenterol Hepatol. 2016; 1: 273-282
        • Li Y.
        • Stocchi L.
        • Rui Y.
        • et al.
        Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection.
        Int J Colorectal Dis. 2016; 31: 1751-1758